Results 231 to 240 of about 30,994 (308)

Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
This graphical summary illustrates the multiorgan therapeutic landscape for Type 2 diabetes mellitus (T2D), integrating molecular pathogenesis with modern treatment strategies. It depicts how current interventions, including SGLT2 inhibitors, GLP‐1 receptor agonists, and insulin secretagogues, target key organs—kidney, pancreas, gastrointestinal tract,
Shinuan Fei, Xiyue Xiong, Lu Zhang, Jian Zhang, Lawrence W. C. Chan, Hong Jiang, Qingqing Xiong, Changtao Hu, Jie Chen, Sijun Yang   +9 more
wiley   +1 more source

Error in Figure 2.

JAMA Intern Med
europepmc   +1 more source

The Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Bone Metabolism. [PDF]

Int J Mol Sci
Lin A, Kitaura H, Ohori F, Marahleh A, Ma J, Fan Z, Narita K, Murakami K, Kanetaka H.   +8 more
europepmc   +1 more source

Reproducibility of Splanchnic Blood Flow Measured Using Phase‐Contrast MRI

NMR in Biomedicine, Volume 39, Issue 8, August 2026.
Splanchnic vessel blood flow assessment can describe physiology or pathophysiological conditions. Here, we assessed the variation of PC‐MRI‐determined repeated measures of blood flow in four splanchnic vessels in three populations and two MRI‐scanners. We found similar agreements with the means for both scanners and for healthy individuals and patients
Lærke S. Gasbjerg, Frederikke H. Østergaard, Rasmus S. Rasmussen, Ludvig S. Langberg, Sophie W. Nielsen, Lotte Alstrup, Tanne S. W. Larsson, Ulrik B. Andersen, Henrik B. W. Larsson, Ali Asmar, Bryan Haddock, Mark B. Vestergaard   +11 more
wiley   +1 more source

A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications

Obesity Science &Practice, Volume 12, Issue 4, August 2026.
ABSTRACT Objective This review synthesized the components of lifestyle interventions that have been provided in Phase 3 trials of obesity management medications (OMMs). Methods PubMed, CINAHL, and EMBASE were searched for Phase 3 clinical trials published from inception to February 2026 that tested FDA‐approved OMMs.
Ariana M. Chao, Ransford Asante, Maame Efua Sersah, Umar Anwar Jahangir, Alexandra Peary, Daniel Kudaya   +5 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis. [PDF]

Adv Ther
Panou T, Gouveri E, Popovic DS, Papanas N.   +3 more
europepmc   +1 more source

Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression. [PDF]

Medicina (Kaunas)
Abenavoli L, Loricchio AG, Lopez I, Morano D, Ismaiel A, Dumitrascu DL, Luzza F.   +6 more
europepmc   +1 more source

Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. [PDF]

Diabetes Obes Metab
Tsakiridis EE, Steinberg GR.
europepmc   +1 more source

A DYRK inhibitor ameliorates glucose homeostasis and increases incretin-producing cells in diabetic mice. [PDF]

J Mol Endocrinol
Terasaki M, Zhou Q, Andersson O, Yamagishi SI.   +3 more
europepmc   +1 more source